Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Antidepressant Use Begins Years Before Alzheimer’s Diagnosis

By Drug Discovery Trends Editor | March 7, 2016

Antidepressants are frequently initiated in persons with Alzheimer’s disease already before the diagnosis, shows a recent study from the University of Eastern Finland. Among persons with Alzheimer’s disease, the initiation of antidepressant use was most common during the six months after the Alzheimer’s diagnosis, and more frequent than among comparison persons without Alzheimer’s disease even 4 years after the diagnosis. The results were published in International Journal of Geriatric Psychiatry.

Antidepressant initiation was more frequent among persons with Alzheimer’s disease already 9 years before the diagnosis than among comparison persons not diagnosed with Alzheimer’s disease. This finding was somewhat surprising. It may be related to more frequent treatment of depressive symptoms because depression has been associated with an increased risk of Alzheimer’s disease in previous studies.

Antidepressant use was investigated in the Finnish nationwide MEDALZ study from 9 years before until 4 years after the diagnosis of Alzheimer’s disease. The difference in antidepressant initiations persisted during the entire follow-up period. During the 13-year follow-up period, 42% of persons with Alzheimer’s disease and 22% of persons not diagnosed with the disease initiated antidepressant use. The most commonly used antidepressant group was selective serotonin reuptake inhibitor (SSRI) drugs, followed by mirtazapine.

The register-based study was based on 62,104 Finnish persons with Alzheimer’s disease diagnosed between 2005 and 2011.

Source: University of Eastern Finland


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50